Controlling lipids in a high-risk population with documented coronary artery disease for secondary prevention: are we doing enough?

Singh, Mukesh; Chin, Shui Hao; Giles, Paul; Crothers, David; Al-Allaf, Karim; Khan, Junaid Sarfraz

doi:10.1097/hjr.0b013e328338978e

Cited by 2 publications

(2 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our objective in this study was to perform a systematic review of the statin literature and quantify the dose-comparative effects of statins on serum lipid levels by combining both placebo-controlled and active-comparator trials. Given the suboptimal lipid control in clinical practice, [9][10][11] this information is necessary as the foundation for evidence-based decision making.…”

Section: Introductionmentioning

confidence: 99%

Dose-comparative effects of different statins on serum lipid levels: a network meta-analysis of 256,827 individuals in 181 randomized controlled trials

Naci

Brugts

Fleurence

et al. 2013

Eur J Prev Cardiolog

View full text Add to dashboard Cite

The findings of this comprehensive review provide supporting evidence for the dose-response relationship of statins in reducing LDL and total cholesterol. The LDL cholesterol-reducing effects of some statins appear less pronounced than the findings of previous meta-analyses, which is particularly the case for the high-dose formulations of atorvastatin and rosuvastatin. The most consistent evidence for a combined reduction in both LDL and total cholesterol was achieved with atorvastatin at >40 mg/day, rosuvastatin at >10 mg/day, and simvastatin at >40 mg/day, which appear equivalent in terms of their LDL and total cholesterol-reducing effects.

show abstract

Section: Introductionmentioning

confidence: 99%

Dose-comparative effects of different statins on serum lipid levels: a network meta-analysis of 256,827 individuals in 181 randomized controlled trials

Naci

Brugts

Fleurence

et al. 2013

Eur J Prev Cardiolog

View full text Add to dashboard Cite

show abstract

“…Recent data indicate that up to 50% of patients treated with a statin who have achieved LDL-C target levels have low HDL-C levels. 10,11 In addition, based on current data, increased TG is nowadays considered to be a significant CVD risk factor. 12 The National Cholesterol Education Prog ram Adult Treatment Panel III (NCEP ATP III) recognized both low HDL-C (,40 mg/dL [1.03 mmol/L] for men, ,50 mg/dL [1.29 mmol/L] for women) and elevated TG levels ($150 mg/dL [1.69 mmol/L]) as markers of increased CVD risk, independently of LDL-C levels.…”

Section: Introductionmentioning

confidence: 99%

Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid

Moutzouri¹,

Kei²,

Elisaf³

et al. 2010

VHRM

View full text Add to dashboard Cite

Cardiovascular disease (CVD) represents the leading cause of mortality worldwide. Lifestyle modifications, along with low-density lipoprotein cholesterol (LDL-C) reduction, remain the highest priorities in CVD risk management. Among lipid-lowering agents, statins are most effective in LDL-C reduction and have demonstrated incremental benefits in CVD risk reduction. However, in light of the residual CVD risk, even after LDL-C targets are achieved, there is an unmet clinical need for additional measures. Fibrates are well known for their beneficial effects in triglycerides, high-density lipoprotein cholesterol (HDL-C), and LDL-C subspecies modulation. Fenofibrate is the most commonly used fibric acid derivative, exerts beneficial effects in several lipid and nonlipid parameters, and is considered the most suitable fibrate to combine with a statin. However, in clinical practice this combination raises concerns about safety. ABT-335 (fenofibric acid, Trilipix ® ) is the newest formulation designed to overcome the drawbacks of older fibrates, particularly in terms of pharmacokinetic properties. It has been extensively evaluated both as monotherapy and in combination with atorvastatin, rosuvastatin, and simvastatin in a large number of patients with mixed dyslipidemia for up to 2 years and appears to be a safe and effective option in the management of dyslipidemia.

show abstract

Controlling lipids in a high-risk population with documented coronary artery disease for secondary prevention: are we doing enough?

Abstract: This study shows widely prevalent low HDL-C levels in high-risk patients across the spectrum of LDL-C levels despite statin therapy. There was no correlation between the LDL-C and HDL-C levels implying their independent relationship and, thus, the need to treat them independently.

Cited by 2 publications

References 34 publications

Dose-comparative effects of different statins on serum lipid levels: a network meta-analysis of 256,827 individuals in 181 randomized controlled trials

Dose-comparative effects of different statins on serum lipid levels: a network meta-analysis of 256,827 individuals in 181 randomized controlled trials

Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid

Contact Info

Product

Resources

About